GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (NAS:HSDT) » Definitions » Return-on-Tangible-Asset

Helius Medical Technologies (Helius Medical Technologies) Return-on-Tangible-Asset : -50.69% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Helius Medical Technologies's annualized Net Income for the quarter that ended in Dec. 2023 was $-4.18 Mil. Helius Medical Technologies's average total tangible assets for the quarter that ended in Dec. 2023 was $8.25 Mil. Therefore, Helius Medical Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -50.69%.

The historical rank and industry rank for Helius Medical Technologies's Return-on-Tangible-Asset or its related term are showing as below:

HSDT' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1284.33   Med: -201.77   Max: -53.82
Current: -76.32

During the past 10 years, Helius Medical Technologies's highest Return-on-Tangible-Asset was -53.82%. The lowest was -1284.33%. And the median was -201.77%.

HSDT's Return-on-Tangible-Asset is ranked worse than
84.34% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: -2.075 vs HSDT: -76.32

Helius Medical Technologies Return-on-Tangible-Asset Historical Data

The historical data trend for Helius Medical Technologies's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helius Medical Technologies Return-on-Tangible-Asset Chart

Helius Medical Technologies Annual Data
Trend Mar14 Mar15 Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.82 -205.02 -198.52 -93.34 -71.33

Helius Medical Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.10 -64.78 -54.16 -150.19 -50.69

Competitive Comparison of Helius Medical Technologies's Return-on-Tangible-Asset

For the Medical Devices subindustry, Helius Medical Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helius Medical Technologies's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Helius Medical Technologies's Return-on-Tangible-Asset falls into.



Helius Medical Technologies Return-on-Tangible-Asset Calculation

Helius Medical Technologies's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-8.85/( (17.147+7.668)/ 2 )
=-8.85/12.4075
=-71.33 %

Helius Medical Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-4.18/( (8.823+7.668)/ 2 )
=-4.18/8.2455
=-50.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Helius Medical Technologies  (NAS:HSDT) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Helius Medical Technologies Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Helius Medical Technologies (Helius Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Executives
Dane Andreeff director, 10 percent owner, officer: President and CEO C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459
Jeffrey S Mathiesen director, officer: CFO and Treasurer 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Favit-van Pelt Antonella R. officer: Chief Medical Officer C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Sherrie L Perkins director 5033 TANGLE LANE, HOUSTON TX 77056
Jennifer Laux officer: Chief Commercial Officer 642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940
Thomas E Griffin director C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Blane Walter director 500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082
Edward M Straw director C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153
Joyce N Laviscount officer: See Remarks 100 ENDO BOULEVARD, CHADDS FORD PA 19317
Huaizheng Peng director HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Philippe Deschamps director, 10 percent owner, officer: President & CEO 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Mitch E Tyler director HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Jonathan Sackier 10 percent owner, officer: Chief Medical Officer HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
A&b (hk) Co Ltd 10 percent owner 8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057

Helius Medical Technologies (Helius Medical Technologies) Headlines

From GuruFocus